

# **Melanoma Reference Handout**

# Melanoma

## Types of Melanoma:

**Cutaneous**  
**Ocular**  
**Mucosal**  
sinonasal, vulvovaginal, anorectal

## Cutaneous Melanoma:

**Superficial Spreading**  
**Nodular**  
**Lentigo Maligna**  
**Acral Lentiginous**  
Rare: Desmoplastic, etc

## IHC:

S100

## Staging: Breslow

### T Size

T1 = 0-1 mm  
T2-T3 = 1-4 mm  
T4 = > 4 mm

### Stage I

0-2 mm

### Stage II

>2 mm

### Stage III

LN+, microsattellites

### Stage IV

Metastatic

## Mutations:

**BRAFV600 (V600E/V600K)**

# Cutaneous Melanoma: Tx

## Stage I, T1 Melanoma (< 1 mm)

### Wide Excision Margins

In situ = 0.5 cm margin  
1 mm depth = 1 cm margin

## Wide Excision +/- SLNB

Consider SLNB if adverse features:  
ulceration, mitotic index > 2/mm<sup>2</sup>, +LVI

## Stage I-II, T2-T3 Melanoma (> 1 mm)

### Wide Excision Margins

1 mm depth = 1 cm margin  
2+ mm depth = 2 cm margin

## Wide Excision + SLNB

If +SLNB → LN US surveillance or completion LND

## Stage III Melanoma (+ LN)

### Wide Excision Margins

1 mm depth = 1 cm margin  
2+ mm depth = 2 cm margin

## Wide Excision + LND

### +/- Adjuvant Systemic Therapy

**BRAF-/+** = pembrolizumab or nivolumab  
**BRAF+** = dabrafenib/trametinib

### +/- Radiation Therapy

## Stage IV Melanoma

### Localized Therapy

Radiation Therapy  
Metastatectomy (oligometastatic)

## Systemic Therapy

### 1. BRAF +/- = Immunotherapy

Pembrolizumab  
Nivolumab +/- Ipilimumab

### 2. BRAF + = BRAF/MEK Inhibitors

Dabrafenib/Trametinib (fever, rash, diarrhea, edema)  
Vemurafenib/Cobimetinib (SCC, QTC)  
Encorafenib/Binimetinib (QTC)